year high 9 times in 3 months

This is part of a report from Macquarie Edge Last month ............... Mesoblast [S&P/ASX 200 Health Care] hits year-high 9th time in three months March 22, 2011 11:00:00 AEST
(News Bites - Trading Floor) 23/03/2011



March 22, 2011 Tuesday



TRADING FLOOR

Mesoblast (MSB.AU), Australia's 2nd largest pharmaceuticals, biotechnology & life sciences company by market capitalisation, hit a 52-week high of $7.0 during the day. In the last three months the stock has hit a new 52-week high nine times, pointing to a significant uptrend. The stock rose for a third day on Tuesday bringing its three-day rise to 10.0c or 1.5%. The stock price rose 6.0c (or 0.9%) to close at $6.94. Compared with the All Ordinaries index, which rose 28.8 points (or 0.6%) on the day, this was a relative price change of 0.3%.

Bullish Signals:

- The price rose 0.9% in the last week and soared 30.9% in the last month.

- This has been propped up by robust volume of 2.2 times average for the week and by firm volume 1.9 times average for the month.

- In the Australian market of 1,080 stocks and 57 units traded today, the stock has a 6-month relative strength of 95 which means it is beating 95% of the market.

- A price rise combined with a high relative strength is a bullish signal.

- The price to 50-day EMAP ratio is 1.2, a bullish indicator. In the past 50 days this ratio has exceeded 1.2 22 times suggesting further upside. The 50-day EMAP has increased to $5.738. An increase is another bullish indicator.

- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) minus the 26-day EMA is positive suggesting a bullish signal. Both the 12-day EMA as well as the 26-day EMA are rising, another bullish signal.

- In the last three months the stock has hit a new 52-week high nine times, pointing to a significant uptrend.

- The price to 200-day MAP ratio is 2.04, a bullish indicator. In the past 200 days this ratio has exceeded 2.04 22 times suggesting further upside. The stock is trading above both its MAPs and the 50-day MAP of $5.819 is higher than the 200-day MAP of $3.409, a bullish indicator.
Cheers V